A Probabilistic Model of Bilateral Lymphatic Spread in Head and Neck Cancer

Roman Ludwig, Yoel Perez Haas, Sergi Benavente, Panagiotis Balermpas, Jan Unkelbach · 2025

Read A Probabilistic Model of Bilateral Lymphatic Spread in Head and Neck Cancer by Roman Ludwig, Yoel Perez Haas, Sergi Benavente, Panagiotis Balermpas, Jan Unkelbach (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2501-16910.txt.

Introduction

Roman Ludwig and co-authors present a medical modeling paper, published in 2025, on how throat cancer spreads through lymph nodes. For oropharyngeal cancer, doctors often treat large parts of the neck on the opposite side with radiation, even when no spread is seen there. The authors build a probability model that estimates hidden disease in each lymph node level for a given patient.

The model treats nodes on both sides of the neck as healthy or involved, linked by chances of spread learned from records of more than eight hundred patients. A tumor crossing the midline emerged as the main risk factor for spread to the other side. The authors aim to help doctors tailor radiation fields to each patient's real risk.

Catalog record

CREATORRoman Ludwig, Yoel Perez Haas, Sergi Benavente, Panagiotis Balermpas, Jan Unkelbach
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2501-16910

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Probabilistic Model of Bilateral Lymphatic Spread in Head and Neck Cancer Roman Ludwig, Yoel Perez Haas, Sergi Benavente, Panagiotis Balermpas, Jan Unkelbach Abstract Purpose: Current guidelines for elective nodal irradiation in oropharyngeal squamous cell carcinoma (OPSCC) recommend including large portions of the contralateral lymphatic system in the clinical target volume (CTV-N), even for lateralized tumors with no clinical lymph node involvement in the contralateral neck. This study introduces a probabilistic model of bilateral lymphatic tumor progression in OPSCC to estimate personalized risks of occult disease in specific lymph node levels (LNLs) based on clinical lymph node involvement, T-stage, and tumor lateralization. Methods: Building on a previously developed hidden Markov model for ipsilateral lymphatic spread, we extend the approach to contralateral neck involvement. The model represents LNLs I, II, III, IV, V, and VII on both sides of the neck as binary hidden variables (healthy or involved), connected via arcs representing spread probabilities. These probabilities are learned using Markov chain Monte Carlo (MCMC) sampling from a dataset of 833 OPSCC patients, enabling the model to reflect the underlying lymphatic progression dynamics. Results: The model accurately and precisely describes observed patterns of lymph node involvement with a compact set of interpretable parameters. Midline extension of the primary tumor is identified as the primary risk factor for contralateral involvement, with advanced T-stage and extensive ipsilateral involvement further increasing risk. Occult disease in contralateral LNL III is highly unlikely if upstream LNL II is clinically negative, and in contralateral LNL IV, occult disease is exceedingly rare without LNL III involvement. Conclusions: This model offers an interpretable, probabilistic framework to inform personalized elective CTV-N volume reduction. For lateralized tumors that do not cross the midline, it suggests the contralateral neck may safely be excluded from elective irradiation. For tumors extending across the midline but with a clinically negative contralateral neck, elective irradiation could be limited to LNL II, reducing unnecessary exposure of normal tissue while maintaining regional tumor control. 1 Introduction In head and neck squamous cell carcinomas (HNSCC) treatments with radiotherapy or surgery, both the primary tumor and clinically detected lymph node metastases are targeted. In addition, current guidelines include large portions of the neck in the elective clinical target volume (CTV-N) ( Grégoire et al. 2003 ; Grégoire et al. 2014 ; Grégoire et al. 2018 ; Eisbruch et al. 2002 ; Biau et al. 2019 ; Chao et al. 2002 ; Vorwerk and Hess 2011 ; Ferlito et al. 2009 ) to mitigate the risk of regional recurrences from untreated microscopic disease undetectable by in-vivo imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). However, this approach must balance minimizing the risk of occult disease in the lymphatic drainage region against the toxicity of unnecessarily irradiating healthy tissue. These CTV-N guidelines rely on anatomically defined lymph node levels (LNLs) ( Grégoire et al. 2014 ) and the overall prevalence of lymph node metastases within these levels. They often recommend extensive irradiation of both sides of the neck. However, the general prevalence of metastasis in a given LNL does not correspond to an individual patient’s risk of occult disease in that region, which depends on their specific state of tumor progression. For example, a patient with no clinically detectable nodal disease (cN0) who has a small, clearly lateralized T1 tumor would receive the same contralateral CTV-N as a patient with significant ipsilateral nodal involvement and an advanced tumor crossing the mid-sagittal plane. Both patients receive elective irradiation of the contralateral LNLs II, III, and IVa ( Biau et al. 2019 ) . To better quantify individualized risk of occult disease, we previously developed an intuitive probabilistic hidden Markov model (HMM) ( Ludwig et al. 2021 ; Ludwig et al. 2023 ) , originally based on a conceptually similar a Bayesian network model ( Pouymayou et al. 2019 ) . However, these models have been limited to predicting ipsilateral nodal involvement. This work extends the model to include contralateral risk predictions, enabling more personalized radiation volume recommendations for the contralateral neck. By identifying patients with low contralateral risk, the model could guide reductions in the contralateral CTV-N, thereby decreasing radiation-induced toxicity and improving quality of life. The main contributions of this paper are as follows: 1. Section 2 presents a multi-centric dataset on lymph node involvement in 833 OPSCC patients, identifying key risk factors for contralateral lymph node involvement and outlining requirements for a bilateral model extension (section 2.4 ). 2. Section 4 introduces a bilateral HMM that incorporates primary tumor lateralization, T-category, and clinical involvement as risk factors for contralateral involvement. Model training and computational experiments are described in section 5 . 3. Section 6 demonstrates the model’s ability to replicate observed contralateral lymph node involvement patterns and estimates occult disease risk for typical patients. Implications for volume-deescalated radiotherapy are discussed in section 8 . 2 Data on Lymphatic Progression Patterns Table 1 : Overview over the four datasets from four different institutions used to train and evaluate our model. Here, we briefly characterize the total number of OPSCC patients from the respective institution, their median age, what proportion received neck dissection, the N0 portion of patients, what percentage presented with early T-category (T1/T2), and the prevalence of primary tumor midline extension. For a much more detailed look at the data, visit lyprox.org . Institution Total Median Age Surgery N0 T1 or T2 Mid. Ext. CLB (Lyon) 325 60 100% 19% 69% 18% ISB (Bern) 74 61 100% 18% 66% 14% USZ (Zurich) 287 66 26% 18% 52% 31% HVH (Barcelona) 147 58 5% 21% 34% 34% To develop models for lymphatic tumor progression for all relevant LNLs, including contralateral regions, we compiled a detailed dataset of 833 patients with newly diagnosed oropharyngeal squamous cell carcinomas (OPSCC) ( Ludwig et al. 2022 ; Ludwig et al. 2024 ) . The dataset includes lymph node involvement per LNL for each patient in tabular form, along with primary tumor and patient characteristics such as T-category, subsite, primary tumor lateralization, and HPV p16 status. Patient records were collected from four institutions, and an overview of patient characteristics is provided in table 1 . Data from the Inselspital Bern (ISB) and Centre Léon Bérard (CLB) consist exclusively of patients who underwent neck dissections. In contrast, the majority of patients from the University Hospital Zürich (USZ) and the Hospital Vall d’Hebron (HVH) were treated with definitive radiotherapy. Since surgical treatment is more common for early T-category patients, ISB and CLB datasets include a higher proportion of these cases compared to USZ and HVH. For 83 patients in the CLB dataset, the primary tumor’s lateralization was not reported. 2.1 Consensus on Involvement Status Pathological involvement is available only for surgically treated patients and for the levels that were dissected. For non-surgical patients, involvement status is determined clinically, i.e. using imaging. For this work, diagnostic information was synthesized into a consensus decision for each patient and LNL. This consensus reflects the most likely state of involvement and accounts for the sensitivity and specificity of various diagnostic modalities, as reported in the literature ( De Bondt et al. 2007 ; Kyzas et al. 2008 ) . The consensus process is detailed in section

Read the complete text